(Q37763151)

22 August 2017

Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006). (English)

1 reference

22 August 2017

1 reference

3

Nicole Yurgin

1 reference

22 August 2017

4

Kristina S Boye

1 reference

22 August 2017

Lizheng Shi

1

1 reference

PubMed ID

20528445

22 August 2017

Meredith Hodges

series ordinal

2

1 reference

22 August 2017

1 April 2007

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

2

1 reference

22 August 2017

187-202

1 reference

Changes in prescribed drug doses after market introduction

22 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Patient adherence to prescribed antimicrobial drug dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Prognostic value of physicians' assessment of compliance regarding all-cause mortality in patients with type 2 diabetes: primary care follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Drug delivery systems improve pharmaceutical profile and facilitate medication adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

The impact of reducing dose frequency on health outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Daily regimen and compliance with treatment. All available evidence needs to be evaluated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Assessment of sulfonylurea adherence and metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Impact of dosage frequency on patient compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

A benefit-risk assessment of extended-release oxybutynin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

How often is medication taken as prescribed? A novel assessment technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Alprazolam extended-release in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

One‐year treatment with standard and sustained‐release levodopa: Appropriate long‐term treatment of restless legs syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

A critical review of compliance studies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Novel oral drug formulations. Their potential in modulating adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

Translating safety, efficacy and compliance into economic value for controlled release dosage forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.2.187

21 January 2018

Identifiers

DOI

10.1586/14737167.7.2.187

1 reference

22 August 2017

1 reference

PubMed ID

20528445